Brief: Novartis: Pluvicto Psmaddition Data To Highlight Efficacy In Metastatic Hormone-Sensitive Prostate Cancer
21/05/2026 06:17
May 21 (Reuters) - NOVARTIS AG NOVN.S: NOVARTIS ADVANCES RLT INNOVATION AND REINFORCES LEADERSHIP IN PROSTATE CANCER, BREAST CANCER AND HEMATOLOGY WITH NEW DATA AT ASCO AND EHA NOVARTIS AG - PLUVICTO PSMADDITION DATA TO HIGHLIGHT EFFICACY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER NOVARTIS AG - KISQALI NATALEE DATA TO REPORT GENE EXPRESSION IMPACT IN CDK4/6I TRIAL NOVARTIS AG - SCEMBLIX ASC4FIRST TO PRESENT 144-WEEK EFFICACY AND SAFETY DATA IN FIRST-LINE PH+ CML-CP NOVARTIS AG - TO PRESENT PHASE 3 IANALUMAB IN ITP AND PHASE 1 ACTINIUM-BASED RLT DATA Source text: ID:nGNE90DyKk Further company coverage: NOVN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'